(KURA) Kura Oncology, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KURA) Kura Oncology, Inc. Complete Analysis Pack
Kura Oncology Business Model Canvas: Strategy, Partnerships, Revenue
Discover how Kura Oncology, Inc. turns clinical innovation into a focused business strategy. This Business Model Canvas breaks down its value proposition, partnerships, and revenue logic in a clear, practical format. Get the full version to see the complete strategic picture and use it for analysis, benchmarking, or investment research.
Partnerships
Novartis alpelisib collaboration
Kura Oncology’s Novartis collaboration tests tipifarnib plus alpelisib in head and neck squamous cell carcinoma, focusing on tumors with HRAS overexpression or PIK3CA mutations/amplifications. This is a precision-oncology bet on two driver pathways in a cancer type that causes about 900,000 new cases globally each year.
Clinical trial sites
Kura Oncology, Inc. relies on oncology hospitals and research centers to enroll patients in 3 main trial areas: AML, ALL, and solid tumors. These sites run protocol-driven studies and biomarker screening, which is critical for generating the clinical data Kura needs to advance its pipeline.
Contract research organizations
Contract research organizations help Kura Oncology, Inc. run multicenter U.S. trials by handling site monitoring, trial operations, and data management. That lowers the need for heavy internal infrastructure, which matters for a clinical-stage company that depends on outside partners to keep studies moving and data clean.
CDMO and manufacturing vendors
Kura Oncology, Inc. relies on CDMO and manufacturing vendors to make clinical supply of its small-molecule programs, including ziftomenib and tipifarnib. These partners handle formulation, scale-up, and quality testing, which lets Kura move faster in development without building full in-house manufacturing capacity.
- External supply for clinical batches
- Supports formulation and scale-up
- Critical for ziftomenib and tipifarnib
Academic and KOL networks
Oncology KOLs shape trial design and patient selection, while academic investigators test biomarker-driven hypotheses in Kura Oncology, Inc.'s precision-oncology studies. That matters because Kura Oncology, Inc. reported $179.3 million in cash, cash equivalents and marketable securities at December 31, 2024, so credible external input helps focus capital on the most defensible programs.
- Improves study design
- Sharpens biomarker selection
- Raises clinical credibility
Kura’s Outsourced Trial Network Extends Its Cash Runway
Kura Oncology, Inc. depends on Novartis, CROs, CDMOs, hospitals, and academic KOLs to fund, run, and de-risk its precision-oncology trials. These ties matter because Kura Oncology, Inc. had $179.3 million in cash, cash equivalents, and marketable securities at December 31, 2024, so outside partners help stretch capital.
| Partner | Role | Why it matters |
|---|---|---|
| Novartis | Tipifarnib plus alpelisib study | Expands combo data |
| CROs | Trial ops and data | Lowers fixed cost |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas showing Kura Oncology’s drug-development pipeline, partnerships, and path to oncology market value creation.
Customizable Excel Spreadsheet
Quickly clarifies Kura Oncology’s business model pain points with a one-page, editable snapshot.
Reference Sources
Kura Oncology, Inc. reference sources provide a clear, traceable trail that boosts credibility and speeds confident decision-making.
Activities
Small-molecule oncology discovery
Kura Oncology, Inc. focuses on small-molecule oncology discovery, advancing targeted therapies like ziftomenib instead of broad cytotoxic drugs. Its precision-medicine pipeline is built for genetically defined cancers, which helps concentrate R&D on patients most likely to benefit.
Clinical development of ziftomenib
Kura Oncology, Inc. is advancing ziftomenib as a menin inhibitor for genetically defined acute leukemias, with clinical proof of concept centered on NPM1-mutant AML and other menin-driven disease subsets. The program moved into late-stage testing in 2025, making trial execution, biomarker-based patient selection, and response data the core value-creating activities.
Clinical development of tipifarnib
Kura Oncology’s key activity is the clinical development of tipifarnib, an oral farnesyl transferase inhibitor in Phase II studies across solid tumors and blood cancers. The program spans monotherapy and combination trials, including in HRAS-mutant tumors and hematologic cancers, with Kura reporting 5 active clinical-stage programs in 2025.
Biomarker-driven patient selection
Kura Oncology, Inc. uses biomarker-driven selection to match patients with HRAS, PIK3CA, and leukemia-linked alterations, which can enrich for responders and cut trial noise. That matters in rare slices too: HRAS mutations show up in about 1% to 4% of solid tumors, PIK3CA in about 20% to 40% of breast cancers, and NPM1-mutant AML in about 25% to 30% of cases.
- Targets mutation-defined patient groups
- Raises response enrichment
- Improves trial efficiency
Regulatory and data package preparation
Kura Oncology, Inc. prepares clinical, safety, and CMC (chemistry, manufacturing, and controls) packages for regulators, then uses Phase 2 and Phase 3 readouts to decide the next step for ziftomenib and other pipeline assets. This work is central in oncology biotech, where one clean filing can move a program from trial data to an FDA review.
- Builds regulator-ready safety and CMC files
- Uses trial readouts for go/no-go calls
- Supports late-stage AML pipeline moves
Kura Oncology Advances Biomarker-Driven Cancer Trials
Kura Oncology’s key activities are biomarker-driven clinical development and trial execution for ziftomenib, tipifarnib, and other oncology programs. In 2025, it reported 5 active clinical-stage programs and pushed ziftomenib into late-stage testing in genetically defined AML.
| Key activity | 2025 data |
|---|---|
| Clinical-stage programs | 5 |
| Ziftomenib status | Late-stage testing |
| Focus | Biomarker-selected cancers |
Preview Before You Purchase
Business Model Canvas
This preview is a direct snapshot of the Kura Oncology, Inc. Business Model Canvas you’ll receive after purchase. It’s not a sample or mockup—what you see here is the exact document, formatted the same way in the final file. Once you buy, you’ll get full access to this same ready-to-use version with no surprises.
Resources
ziftomenib asset
Ziftomenib is Kura Oncology, Inc.'s lead small-molecule asset and the core of its acute leukemia plan. It targets menin-KMT2A interaction biology, a validated pathway in KMT2A-rearranged and NPM1-mutated AML, and anchors the Company Name's clinical pipeline and future value creation.
tipifarnib asset
Tipifarnib is Kura Oncology, Inc.’s other major clinical asset: an oral farnesyl transferase inhibitor built to block the RAS pathway. It helps broaden the pipeline beyond one indication, reducing concentration risk and giving Kura more than one path to future value.
Clinical trial data
Clinical trial data is Kura Oncology, Inc.'s core knowledge asset: the Company uses readouts from its menin inhibitor program, including ziftomenib, to make go or no-go calls, support publications, and guide partnering talks. The value is concentrated in late-stage evidence, especially 1 Phase 3 path and multiple earlier studies that shape each program’s risk, label, and deal potential.
Intellectual property portfolio
Kura Oncology, Inc. relies on patents and proprietary chemistry to protect its pipeline, which still had no product revenue in 2025. That IP base is key to future commercialization and partnering, because it can raise the value of each development candidate and support licensing terms.
- Patents defend the pipeline.
- IP supports future licensing.
- Stronger IP can lift asset value.
Scientific team and headquarters
Kura Oncology, Inc. is headquartered in San Diego, California, and its scientific and clinical teams are the core asset behind discovery and development. In fiscal 2025, it reported $149.2 million in research and development expense, showing how heavily the company depends on human capital to advance its clinical-stage pipeline.
- San Diego headquarters
- Scientific and clinical staff drive R&D
- Human capital is the key resource
Kura’s Future Rests on Ziftomenib, Tipifarnib, and Heavy R&D Spend
Kura Oncology, Inc.'s key resources are its lead assets, ziftomenib and tipifarnib, plus the clinical data and IP that support them. In fiscal 2025, research and development expense was $149.2 million, showing how central scientific talent and trial execution are to the model.
| Resource | 2025 data | Why it matters |
|---|---|---|
| Ziftomenib | Lead asset | Menin program |
| R&D | $149.2m | Human capital |
Value Propositions
Targeted precision oncology
Kura Oncology, Inc. builds therapies for defined genetic cancer subtypes, aiming to match each mechanism to the tumor’s biology rather than using broad treatment. This precision fit can lift response rates versus non-selected care; for example, its menin inhibitor ziftomenib moved into late-stage testing in 2025 for NPM1-mutated acute myeloid leukemia.
Oral small-molecule candidates
Kura Oncology, Inc.'s two lead assets, tipifarnib and ziftomenib, are small-molecule drugs built for systemic treatment. Tipifarnib is orally administered, and oral dosing for both candidates supports outpatient use, lower treatment burden, and easier patient convenience.
Focus on high-need leukemias
Ziftomenib targets acute leukemias with defined genetic drivers, especially NPM1-mutated and KMT2A-rearranged disease. AML still causes about 20,800 new U.S. cases a year, and 5-year survival is only about 31%, while adult ALL remains hard to treat and often relapses.
Combination therapy potential
Kura Oncology, Inc. builds tipifarnib and other programs for both standalone use and combinations, and its Novartis study pushes tipifarnib into rational combo therapy. This matters because combination approaches can lift response in resistant tumors; Kura Oncology, Inc. reported $370.8 million in cash, cash equivalents, and investments at 2025 year-end.
- Standalone and combo design
- Novartis study expands tipifarnib use
- Can reach resistant tumors
Biomarker-enriched solid tumors
Tipifarnib is being tested in biomarker-defined solid tumors, with HRAS and PIK3CA alterations used to pick patients most likely to respond. That supports a differentiated oncology label strategy because it narrows use to defined genotypes instead of broad, hard-to-win tumor groups.
- Focuses on biomarker-selected patients
- Uses HRAS and PIK3CA markers
- Supports a differentiated label
Kura Oncology: Precision Cancer Bets Backed by $370.8M in Liquidity
Kura Oncology, Inc. targets genomically defined cancers with oral small molecules, so value comes from matching therapy to mutation, not broad use. Its lead programs, tipifarnib and ziftomenib, focus on hard-to-treat AML and solid tumors with biomarker selection.
| Value driver | Key data |
|---|---|
| Lead assets | Tipifarnib, ziftomenib |
| 2025 year-end liquidity | $370.8 million |
| Core patient focus | NPM1, KMT2A, HRAS, PIK3CA |
Customer Relationships
Clinical investigator collaboration
Kura Oncology, Inc. works closely with principal investigators and study teams across its 2 lead clinical programs, and that tie is key for protocol execution and patient enrollment. In a trial-stage model, these relationships drive site speed, data quality, and readouts that can move R&D spending and value.
Medical science engagement
Kura Oncology, Inc. uses direct scientific dialogue with oncologists and KOLs to sharpen trial design and read emerging data faster, which matters in precision oncology. As of its latest reported fiscal year, Kura Oncology held $373.3 million in cash, cash equivalents, and marketable securities, giving it room to sustain this evidence-driven engagement.
Partner governance with Novartis
Kura Oncology, Inc. and Novartis use formal joint governance and shared study oversight to run their alliance, which keeps combo development decisions aligned. That structure matters in oncology, where trial milestones, dose changes, and go/no-go calls can shift quickly.
The setup also helps both sides coordinate clinical work without delays, so decisions on patient data and next-step studies stay tied to the same plan.
Regulatory interaction management
Kura Oncology, Inc. keeps active regulator contact through IND, safety, and trial-design talks, which helps move programs like ziftomenib through phase gates. These interactions are central to approvals: one missed safety signal can stall a study, so regulator access is a key relationship asset.
- IND and safety reviews guide trial moves
- Ongoing talks support phase progression
Investor and public-market communication
Kura Oncology, Inc. keeps investors updated through earnings calls, SEC filings, and pipeline updates on trial readouts, regulatory steps, and funding needs. For a public biotech, that steady communication is key to capital access, since the company must support ongoing R&D while managing cash burn.
- Shares pipeline and trial progress
- Explains financing and runway needs
- Supports access to public capital
Kura Oncology’s Key Relationships and $373.3M Cash Position
Kura Oncology, Inc. builds customer relationships mainly through tight ties with clinical investigators, oncologists, regulators, and Novartis, since these groups shape trial speed, safety, and go/no-go calls. It also keeps investors informed through SEC filings and earnings updates; as of its latest reported fiscal year, cash, cash equivalents, and marketable securities were $373.3 million.
| Relationship | Why it matters | Latest data |
|---|---|---|
| Investors | Funds R&D runway | $373.3 million cash and securities |
Channels
Clinical trial sites
In 2025, Kura Oncology, Inc. routed patients into ziftomenib and tipifarnib studies through specialized oncology research sites, where enrollment stays concentrated in expert cancer centers. This channel fits biomarker-driven trials, since patients usually need site-based screening and close protocol oversight before joining the company’s programs.
Scientific conferences
Kura Oncology uses scientific conferences to share clinical readouts on oncology meetings and congresses, where peer review helps validate data and sharpen the story. Major forums like ASCO draw about 40,000 attendees, giving Kura reach to investigators, partners, and investors in one place.
Peer-reviewed publications
Peer-reviewed publications turn Kura Oncology, Inc.’s Phase 1/2 and Phase 3 data into citable proof of mechanism and efficacy in hematology and oncology. They add third-party validation for the pipeline and help broaden scientific awareness beyond company channels.
Partner networks
Partner networks let Kura Oncology, Inc. reach more development expertise and broader patient pools without building every site alone. The Novartis collaboration is the clearest example: it supports faster combination study setup and shared clinical execution, which matters in a pipeline focused on precision oncology.
- Broader trial reach
- Shared development skills
- Faster combo studies
- Novartis is key
Investor relations
Kura Oncology, Inc. uses investor relations as a core channel: 4 quarterly updates, 4 earnings calls, and SEC filings (10-Q and 10-K) keep the market current on pipeline status and cash needs. For a development-stage biotech, this is critical because funding and trial milestones drive valuation.
- 4 quarterly updates a year
- 4 earnings calls a year
- 10-Q and 10-K filings
- Shares pipeline and cash needs
Kura Oncology Keeps ziftomenib and tipifarnib in the Spotlight
Kura Oncology, Inc. channels its pipeline through expert oncology trial sites, major medical congresses, peer-reviewed journals, partner networks, and investor relations. In 2025, the company reported 4 quarterly updates, 4 earnings calls, and SEC filings to keep ziftomenib and tipifarnib progress visible.
| Channel | Role | 2025 |
|---|---|---|
| Trial sites | Biomarker screening | Specialized centers |
| Congresses | Data disclosure | ASCO about 40,000 attendees |
| IR | Market updates | 4 updates, 4 calls |
Customer Segments
Patients with AML
Patients with AML are a core target for Kura Oncology, Inc.’s ziftomenib, especially genetically defined groups like NPM1-mutated and KMT2A-rearranged disease. AML still causes about 20,000 new U.S. cases a year and has roughly a 30% 5-year survival rate, so the unmet medical need remains high.
Patients with ALL
Patients with ALL are a rare hematologic segment for ziftomenib, with U.S. incidence at about 6,100 new cases a year and around 1,400 deaths. Kura Oncology, Inc. focuses on genetically defined subgroups, which supports precision enrollment and a tighter fit for small, high-need ALL populations.
Patients with solid tumors
Kura Oncology’s solid-tumor customers are mainly patients with biomarker-selected cancers, especially HRAS-mutant head and neck squamous cell carcinoma in the Novartis collaboration. Tipifarnib’s biomarker gate keeps the eligible pool tight, since HRAS mutations appear in only about 4% to 8% of head and neck squamous cell carcinoma cases.
Oncology treatment centers
Oncology treatment centers are Kura Oncology, Inc.'s core clinical customers: hospitals and cancer centers enroll patients, run protocols, and collect the safety and response data needed for development-stage drugs. In practice, this matters because cancer care is concentrated in a few large networks; the U.S. has 70+ NCI-designated cancer centers, which makes these sites the key gateway to trial access.
- Enroll trial patients
- Administer study protocols
- Generate clinical data
Pharmaceutical partners
Pharmaceutical partners are a key customer segment for Kura Oncology, Inc. They help fund and run combination trials, support licensing, and can back future commercialization. Novartis is the clearest current example: Kura Oncology, Inc. and Novartis are studying ziftomenib in a global Phase 1/2 trial for NPM1-mutant AML, a setting that affects about 30% of adult AML cases.
- Partners lower trial and launch risk
- Novartis is the lead example
- Combo studies expand drug reach
Kura Targets Rare Mutations in AML, ALL, and Solid Tumors
Kura Oncology, Inc. serves genetically defined patients with AML, ALL, and solid tumors, plus the hospitals and pharma partners that enroll, run, and fund trials. The biggest patient pools are AML at about 20,000 U.S. cases a year and ALL at about 6,100, while HRAS-mutant HNSCC is a much smaller biomarker niche at roughly 4% to 8% of cases.
| Segment | Key data |
|---|---|
| Patients | AML, ALL, HRAS-mutant solid tumors |
| Sites | 70+ NCI centers |
| Partners | Novartis ziftomenib Phase 1/2 |
Cost Structure
Clinical trial spending
Clinical trial spending is Kura Oncology, Inc.’s biggest cost driver because it funds site fees, patient monitoring, and data collection across programs. In FY2025, research and development spending stayed the main cash drain, reflecting the cost of running more than one clinical program at once and the heavy outlay needed to advance ziftomenib and other pipeline assets.
Research and development payroll
Kura Oncology, Inc.’s research and development payroll is a fixed, recurring cost tied to scientists, clinicians, and development staff who run discovery, biomarker work, and trial management. In 2025, research and development remained its largest expense line, reflecting a workforce built to support multiple clinical programs rather than a variable cost base.
Manufacturing and CMC
Kura Oncology, Inc. is still pre-revenue, so manufacturing and CMC spend sits in R&D and grows as programs move from lab batches to clinical supply. Clinical supply production needs formulation, QC, and release testing, and small-molecule scale-up adds chemistry and manufacturing costs as each program advances.
Regulatory and compliance
Kura Oncology, Inc. must carry IND maintenance, safety reporting, legal review, and SEC filing work as fixed overhead, because biotech development cannot move forward without them. In 2025, these costs sat alongside public-company reporting duties, which add recurring legal, audit, and disclosure spend on top of R&D.
- IND upkeep is mandatory.
- Safety reporting adds routine cost.
- Public filings raise compliance spend.
Intellectual property and IP defense
Kura Oncology, Inc. spends on patent filing, maintenance, and enforcement to protect its oncology pipeline; core U.S. patents generally run 20 years from filing, and those costs rise fast in crowded cancer drug fields where legal fights can run into millions. This IP spend helps preserve licensing leverage and future commercialization value.
- Patent filings protect candidate value
- Defense costs can be material
- Supports licensing and launch options
Kura’s FY2025 Costs Stay R&D-Heavy as Losses Widen
Kura Oncology, Inc.’s cost structure is still R&D-led: FY2025 research and development was $181.7 million, driven by ziftomenib trials, clinical supply, and a full development team. G&A was $65.8 million, covering public-company, legal, and IP costs. Noncash stock compensation added to fixed overhead.
| FY2025 | USD mn |
|---|---|
| R&D | 181.7 |
| G&A | 65.8 |
| Total op. loss | 247.5 |
Revenue Streams
Collaboration revenue
Kura Oncology, Inc. can earn collaboration revenue from pharma deals through upfront fees, R&D support, and shared-development cost reimbursements. The Novartis partnership is the clearest model: it gives Kura access to shared economics, with up to $1.1 billion in development, regulatory, and sales milestones plus royalties.
Milestone payments
Milestone payments are a core biotech revenue stream for Kura Oncology, Inc., usually tied to trial progress, FDA or other regulator events, and first commercial sales. They are contingent on program success, so cash can stay lumpy; in FY2025, Kura still relied on partnership-linked, non-recurring inflows rather than steady product sales.
R and D reimbursement
Kura Oncology, Inc. uses partner R&D reimbursement to offset part of development costs in collaborative studies, especially combo trials. In its latest filings, this kind of support helps cut net cash burn by shifting some trial spend to partners, which is important as the company advances ziftomenib and other joint programs.
Future product sales
If approved, ziftomenib and tipifarnib could drive direct oncology drug sales, with demand focused on biomarker-selected patients, not broad primary-care use. As of Kura Oncology, Inc.'s 2025 reporting, product revenue was still $0, so this remains the company’s long-term revenue path.
- Direct sales from approved drugs
- Biomarker-selected cancer patients
- Long-term revenue, not current revenue
Licensing income
Kura Oncology, Inc. can license assets by region or indication to pull in upfront cash now and royalties later; this is a standard path for clinical-stage oncology firms that still have 0 commercial product sales. It helps fund R&D without issuing more shares, while keeping upside if a partner advances the asset.
- Upfront fees improve near-term cash.
- Royalties add long-tail upside.
- Regional deals reduce capital needs.
Kura’s 2025 Revenue Is Still Partner-Driven, Not Product-Sales Driven
Kura Oncology, Inc. still has no product sales in FY2025, so revenue streams stay partner-led: upfront fees, R&D reimbursements, and contingent milestones from deals like Novartis, which can pay up to $1.1 billion plus royalties.
This makes revenue lumpy and trial-driven, with ziftomenib as the main long-term product-sales path if approvals come.
| Stream | FY2025 status |
|---|---|
| Product sales | $0 |
| Novartis milestones | Up to $1.1B |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.